The role of percutaneous hepatic perfusion (PHP) in the treatment of cholangiocarcinoma

Abstract

This review article evaluates the current literature on the role of percutaneous hepatic perfusion (PHP) as a treatment option in cholangiocarcinoma (CCA). CCA is a rare cancer that is mostly diagnosed at a late stage. Patients with advanced, unresectable disease have limited treatment options. PHP is a locoregional therapy that delivers high doses of chemotherapy directly to the liver while minimizing systemic exposure and toxicity. This review allocates PHP in the therapeutic spectrum of CCA and summarizes the available literature with a focus on the clinical efficacy and safety profile. Results from studies evaluating the efficacy and safety of PHP are promising, with several observational studies demonstrating improvements in progression-free survival and overall survival rates. However, PHP is not without side effects; the most commonly reported adverse events include transient hematotoxicity and hepatotoxicity. PHP has the potential to be a valuable treatment option for patients with unresectable CCA. Nonetheless, further trials are needed to optimize patient selection, treatment regimens, and long-term outcomes.

Keywords

Cholangiocarcinoma / intraarterial therapies / percutaneous hepatic perfusion / locoregional therapy

References

[1] Dewald CLA,Meine TC.New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option.Clin Exp Metastasis2023;40:95-104 PMCID:PMC9898387

[2] S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. Diagnostik und therapie des hepatozellulären karzinoms und biliärer karzinome. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome/ [Last accessed on 13 Mar 2024]

[3] Koch C,Bechstein WO.Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center.Digestion2020;101:458-65

[4] Bridgewater J,Khan SA.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014;60:1268-89

[5] Jansen H,Utku N.A review of systemic therapy in biliary tract carcinoma.J Gastrointest Oncol2020;11:770-89 PMCID:PMC7475338

[6] Vashist Y,Gailhofer S.Therapeutic effect of regional chemotherapy in diffuse metastatic cholangiocarcinoma.Cancers2022;14:3701 PMCID:PMC9367530

[7] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[8] Gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel in treating patients with newly diagnosed advanced biliary tract cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT03768414 [Last accessed on 13 Mar 2024]

[9] Lamarca A,Wasan HS.Advanced Biliary Cancer Working GroupSecond-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Lancet Oncol2021;22:690-701 PMCID:PMC8082275

[10] Ferrucci PF,Bonomo G,Della Vigna P.A new option for the treatment of intrahepatic cholangiocarcinoma: percutaneous hepatic perfusion with CHEMOSAT delivery system.Cells2021;10:70 PMCID:PMC7824743

[11] Horesh N,Lim C,Meirson T.Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect.Hepatobiliary Surg Nutr2022;11:861-9 PMCID:PMC9745612

[12] Vogel A,Edeline J.ESMO Guidelines CommitteeBiliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023;34:127-40

[13] Edeline J,McNamara MG.Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis.Cancer Treat Rev2021;99:102258

[14] Corte AD,Steidler S.Radiological imaging and non-surgical local treatments for cholangiocarcinoma.Hepatoma Res2022;8:5

[15] Kennedy A,Sangro B,Salem R.Radioembolization for the treatment of liver tumors general principles.Am J Clin Oncol2012;35:91-9

[16] Alexander HR Jr,Libutti SK,Moser T.Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.J Clin Oncol1998;16:1479-89

[17] Hughes MS,Faries M.Results of a randomized controlled multicenter phase iii trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases.Ann Surg Oncol2016;23:1309-19 PMCID:PMC8185532

[18] Pingpank JF,Chang R.Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.J Clin Oncol2005;23:3465-74 PMCID:PMC2374756

[19] Kirstein MM,Jedicke N.Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.J Cancer Res Clin Oncol2017;143:2113-21

[20] Schönfeld L,Marquardt S.Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.J Cancer Res Clin Oncol2020;146:3003-12 PMCID:PMC7519914

[21] Dewald CLA,Brüning R.Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience.Cancers2021;14:118 PMCID:PMC8749811

[22] Brüning R,Schneider M.Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan-long-term overall survival negatively correlates with tumor burden.Radiol Res Pract2020;2020:5672048 PMCID:PMC7484678

[23] Karydis I,Wheater MJ.Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.J Surg Oncol2018;117:1170-8 PMCID:PMC6033148

[24] Artzner C,Hefferman G.Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.Cancer Imaging2019;19:31 PMCID:PMC6543599

[25] Dewald CLA,Winther HMB.Chemosaturation percutaneous hepatic perfusion (CS-PHP) with melphalan: evaluation of 2D-perfusion angiography (2D-PA) for leakage detection of the venous double-balloon catheter.Cardiovasc Intervent Radiol2019;42:1441-8

[26] Dewald CLA,Maschke SK.Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.Clin Exp Metastasis2020;37:683-92 PMCID:PMC7666275

[27] Vogel A,Zeile M.Chemosaturation percutaneous hepatic perfusion: a systematic review.Adv Ther2017;33:2122-38 PMCID:PMC5126197

[28] Struck MF,Ebel S.Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery.PLoS One2021;16:e0254817 PMCID:PMC8284610

[29] Forster MR,Perez MC,Chaudhry T.Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.J Surg Oncol2014;109:434-9 PMCID:PMC4503311

[30] Wacker F.[Local and locoregional treatment of intrahepatic cholangiocarcinoma].Radiologe2022;62:247-52

[31] Samuels BL.High-dose intravenous melphalan: a review.J Clin Oncol1995;13:1786-99

[32] Meijer TS,Fiocco M.Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the delcath systems' second-generation hemofiltration system: a prospective non-randomized phase II trial.Cardiovasc Intervent Radiol2019;42:841-52 PMCID:PMC6502784

[33] Veelken R,Strocka S.Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers.Cardiovasc Intervent Radiol2022;45:218-22 PMCID:PMC8555734

[34] Marquardt S,Brüning R.Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.Eur Radiol2019;29:1882-92

[35] Facchetti N,Becker LS.Heparin reversal with protamine sulfate after percutaneous hepatic perfusion (PHP): is less more?.Cancer Imaging2023;23:68 PMCID:PMC10349410